METTL14 modulates glycolysis to inhibit colorectal tumorigenesis in p53‐wild‐type cells

The frequency of p53 mutations in colorectal cancer (CRC) is approximately 40–50%. A variety of therapies are being developed to target tumors expressing mutant p53. However, potential therapeutic targets for CRC expressing wild‐type p53 are rare. In this study, we show that METTL14 is transcription...

Descripción completa

Detalles Bibliográficos
Autores principales: Hou, Yichao, Zhang, Xintian, Yao, Han, Hou, Lidan, Zhang, Qingwei, Tao, Enwei, Zhu, Xiaoqiang, Jiang, Shanshan, Ren, Yimeng, Hong, Xialu, Lu, Shiyuan, Leng, Xiaoxu, Xie, Yile, Gao, Yaqi, Liang, Yu, Zhong, Ting, Long, Bohan, Fang, Jing‐Yuan, Meng, Xiangjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10074077/
https://www.ncbi.nlm.nih.gov/pubmed/36794620
http://dx.doi.org/10.15252/embr.202256325

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10074077/
https://www.ncbi.nlm.nih.gov/pubmed/36794620
http://dx.doi.org/10.15252/embr.202256325

Ejemplares similares